TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07126262: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months

Sponsor: BioMarin Pharmaceutical · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT07126262 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07126262 Rescue Dossier →